[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Boundless Bio Inc (BOLD)

Boundless Bio Inc (BOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,385
  • Shares Outstanding, K 22,464
  • Annual Sales, $ 0 K
  • Annual Income, $ -58,200 K
  • EBIT $ -61 M
  • EBITDA $ -59 M
  • 60-Month Beta 0.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.70
  • Growth Rate Est. (year over year) +142,814.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.38 +83.33%
on 06/11/26
2.79 -9.32%
on 06/24/26
+1.06 (+72.11%)
since 05/26/26
3-Month
1.07 +136.45%
on 04/02/26
2.79 -9.32%
on 06/24/26
+1.42 (+127.93%)
since 03/26/26
52-Week
0.96 +163.21%
on 02/05/26
2.79 -9.32%
on 06/24/26
+1.46 (+136.45%)
since 06/26/25

Most Recent Stories

More News
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

REFI : 11.18 (+1.36%)
TECH : 70.95 (+0.35%)
APGE : 132.65 (-0.02%)
BOLD : 2.50 (-0.40%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)

NEW YORK , June 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...

BOLD : 2.50 (-0.40%)
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior...

BOLD : 2.50 (-0.40%)
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement

Combined company to operate as Serapha Bio and to advance Serapha’s potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha’s lead program SERP-01 targets...

BOLD : 2.50 (-0.40%)
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights

Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May...

BOLD : 2.50 (-0.40%)
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...

BOLD : 2.50 (-0.40%)
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...

BOLD : 2.50 (-0.40%)
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1...

BOLD : 2.50 (-0.40%)
Boundless Bio to Participate in the Leerink Global Healthcare Conference

SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...

BOLD : 2.50 (-0.40%)
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...

BOLD : 2.50 (-0.40%)

Business Summary

Boundless Bio Inc. is a clinical stage oncology company interrogating extrachromosomal DNA biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers. Boundless Bio Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 2.83
2nd Resistance Point 2.73
1st Resistance Point 2.62
Last Price 2.50
1st Support Level 2.41
2nd Support Level 2.31
3rd Support Level 2.20

See More

52-Week High 2.79
Last Price 2.50
Fibonacci 61.8% 2.09
Fibonacci 50% 1.88
Fibonacci 38.2% 1.66
52-Week Low 0.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.